Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Albany Medical Center Hospital
Docetaxel and celecoxib inhibited non-small cell lung cancer
June 22nd, 2005
Administrating docetaxel and celecoxib in concert could inhibit advanced non-small cell lung cancer. In a recently published article, scientists in the United States conducted a study "to assess the overall and progression-free survival, response rate, and toxicity of combined docetaxel and celecoxib in the treatment of patients with non-small cell lung cancer progressing after initial chemotherapy for advanced disease." "Patients with non-small cell lung cancer and either measurable or evaluable disease experiencing progression after one or more platinum-based chemotherapy regimens given for advanced or metastatic disease, ECOG performance status...
Source: Physician Law Weekly (2005-06-22)
|
